Objective To systematically summarize the application prospects of post-translational modifications of programmed death-1 (PD-1) in tumor immunotherapy, and provide new ideas for the immunotherapy of tumor patients. MethodsBased on the immunosuppressive mechanism of PD-1 and the clinical application status of anti PD-1 immunotherapy, combined with the existing research results on PD-1 post-translational modifications, this study systematically sorted out and analyzed the types of post-translational modifications of PD-1, their regulatory mechanisms, and their association with immunotherapy. ResultsPD-1 is an immunosuppressive molecule expressed on the surface of activated T cells, B cells and other cells. After binding to programmed death-ligand 1, it can negatively regulate the immune system. Anti PD-1/programmed death-ligand 1 immunotherapy has been widely used in the treatment of various malignant tumors, but some patients have poor response. PD-1 has various post-translational modifications such as phosphorylation, glycosylation, ubiquitination and palmitoylation, which can affect the stability and physiological functions of PD-1. ConclusionsPost-translational modifications of PD-1 are a key mechanism regulating the tumor immune evasion. Targeting the post-translational modification process of PD-1 is expected to improve the response of tumor immunotherapy and have good clinical application prospects.
